Risk Factors for Recurrence of Primary Biliary Cholangitis After Liver Transplantation in Female Patients: A Japanese Multicenter Retrospective Study

被引:15
作者
Kogiso, Tomomi [1 ]
Egawa, Hiroto [2 ]
Teramukai, Satoshi [3 ]
Taniai, Makiko [1 ]
Hashimoto, Etsuko [1 ]
Tokushige, Katsutoshi [1 ]
Sakisaka, Shotaro [4 ]
Sakabayashi, Satomi [5 ]
Yamamoto, Masakazu [2 ]
Umeshita, Koji [6 ]
Uemoto, Shinji [7 ]
机构
[1] Tokyo Womens Med Univ, Inst Gastroenterol, Dept Internal Med, Tokyo, Japan
[2] Tokyo Womens Med Univ, Inst Gastroenterol, Dept Surg, Tokyo, Japan
[3] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Biostat, Kyoto, Japan
[4] Fukuoka Univ, Dept Gastroenterol, Fukuoka, Fukuoka, Japan
[5] Kyoto Prefectural Univ Med, Ctr Qual Assurance Res & Dev, Kyoto, Japan
[6] Osaka Univ, Grad Sch Med, Dept Surg, Osaka, Japan
[7] Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto, Japan
关键词
URSODEOXYCHOLIC ACID TREATMENT; LONG-TERM SURVIVAL; DISEASE RECURRENCE; HEPATOCELLULAR-CARCINOMA; HISTOLOGICAL EVIDENCE; CYCLOSPORINE-A; FOLLOW-UP; CIRRHOSIS; IMMUNOSUPPRESSION; BEZAFIBRATE;
D O I
10.1002/hep4.1037
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Primary biliary cholangitis (PBC) is diagnosed mainly in female individuals, and risk factors for PBC recurrence (rPBC) after liver transplantation (LT) from cadaveric donors have been reported. We conducted a retrospective multicenter study of rPBC in female patients after living-donor LT (LDLT). A total of 388 female patients undergoing LDLT for end-stage PBC were enrolled, and the effects of preoperative and operative factors were evaluated. Postoperative factors were evaluated in 312 patients who survived for more than 1 year post-LDLT. rPBC was defined as abnormal hepatic enzyme levels with typical histological findings in liver biopsies. Fifty-eight patients (14.9%) developed rPBC with a median of 4.6 (0.8-14.5) years post-LT. Cox hazard analysis (P < 0.05) showed that younger recipient age (hazard ratio, 0.95; 95% confidence interval, 0.920-0.982), shorter operative time (1.00; 0.995-0.999), higher serum immunoglobulin M level (1.00; 1.001-1.002), donor sex mismatch (2.45; 1.268-4.736), human leukocyte antigen B60 (2.56; 1.336-4.921) and DR8 (1.98; 1.134-3.448), and initial treatment with cyclosporine A (3.14; 1.602-6.138) were significantly associated with rPBC. The frequencies of Child-Turcotte-Pugh class C (0.46; 0.274-0.775), the model of end-stage liver disease score (0.96; 0.914-0.998), and updated Mayo risk score (1.02; 1.005-1.033) were significantly lower in rPBC. Posttransplantation use of steroids decreased and that of antimetabolites increased the frequency of rPBC. Conclusion: The timing of LT, recipient conditions, donor characteristics, and immunosuppressive medications may be associated with rPBC in LT recipients.
引用
收藏
页码:394 / 405
页数:12
相关论文
共 58 条
[21]   Warm ischemia in transplantation: Search for a consensus definition [J].
Halazun, K. J. ;
Al-Mukhtar, A. ;
Aldouri, A. ;
Willis, S. ;
Ahmad, N. .
TRANSPLANTATION PROCEEDINGS, 2007, 39 (05) :1329-1331
[22]   Disease recurrence after living liver transplantation for primary biliary cirrhosis: A clinical and histological follow-up study [J].
Hashimoto, E ;
Shimada, M ;
Noguchi, S ;
Taniai, M ;
Tokushige, K ;
Hayashi, N ;
Takasaki, K ;
Fuchinoue, S ;
Ludwig, J .
LIVER TRANSPLANTATION, 2001, 7 (07) :588-595
[23]   Long-term clinical outcome of living-donor liver transplantation for primary biliary cirrhosis [J].
Hashimoto, Etsuko ;
Taniai, Makiko ;
Yatsuji, Satoru ;
Tokushige, Katsutoshi ;
Shiratori, Keiko ;
Yamamoto, Masakazu ;
Fuchinoue, Syouhei .
HEPATOLOGY RESEARCH, 2007, 37 :S455-S461
[24]   Effects of Immunosuppressive Drugs On Purified Human B Cells: Evidence Supporting the Use of MMF and Rapamycin [J].
Heidt, Sebastiaan ;
Roelen, Dave L. ;
Eijsink, Chantal ;
van Kooten, Cees ;
Claas, Frans H. J. ;
Mulder, Arend .
TRANSPLANTATION, 2008, 86 (09) :1292-1300
[25]   PRIMARY BILIARY-CIRRHOSIS - HISTOLOGICAL EVIDENCE OF DISEASE RECURRENCE AFTER LIVER-TRANSPLANTATION [J].
HUBSCHER, SG ;
ELIAS, E ;
BUCKELS, JAC ;
MAYER, AD ;
MCMASTER, P ;
NEUBERGER, JM .
JOURNAL OF HEPATOLOGY, 1993, 18 (02) :173-184
[26]   Frequency of monosomy X in women with primary biliary cirrhosis [J].
Invernizzi, P ;
Miozzo, M ;
Battezzati, PM ;
Bianchi, I ;
Grati, FR ;
Simoni, G ;
Selmi, C ;
Watnik, M ;
Gershwin, ME ;
Podda, M .
LANCET, 2004, 363 (9408) :533-535
[27]   Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis [J].
Itakura, J ;
Izumi, N ;
Nishimura, Y ;
Inoue, K ;
Ueda, K ;
Nakanishi, H ;
Tsuchiya, K ;
Hamano, K ;
Asahina, Y ;
Kurosaki, M ;
Uchihara, M ;
Miyake, S .
HEPATOLOGY RESEARCH, 2004, 29 (04) :216-222
[28]   Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients [J].
Jacob, DA ;
Neumann, UP ;
Bahra, M ;
Klupp, J ;
Puhl, G ;
Neuhaus, R ;
Langrehr, JM .
CLINICAL TRANSPLANTATION, 2006, 20 (02) :211-220
[29]   Liver transplantation for primary biliary cirrhosis: Influence of primary immunosuppression on survival [J].
Jacob, DA ;
Neumann, UP ;
Bahra, M ;
Langrehr, JM ;
Neuhaus, P .
TRANSPLANTATION PROCEEDINGS, 2005, 37 (04) :1691-1692
[30]   Long-term outcome of living donor liver transplantation for primary biliary cirrhosis [J].
Kaneko, Junichi ;
Sugawara, Yasuhiko ;
Tamura, Sumihito ;
Aoki, Taku ;
Hasegawa, Kiyoshi ;
Yamashiki, Noriyo ;
Kokudo, Norihiro .
TRANSPLANT INTERNATIONAL, 2012, 25 (01) :7-12